Compare Twist Bioscience Corp (TWST) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Under Armour Inc Class A — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Under Armour Inc Class A trades at $4.82 (market cap $2.15B). The key difference: Twist Bioscience Corp is far larger — about 3.9× Under Armour Inc Class A's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| TWST | UA | |
|---|---|---|
Market Cap | $8.42B | $2.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $153.10 | $7.88 |
52-Week Low | $24.16 | $3.96 |
Enterprise Value | $8.35B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Under Armour (UA) trades at $4.95, down 3.32% amid bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -9.99% and declining revenue trends. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. Cash flow remains negative, and the company faces challenges from softer consumer demand in key markets.
The outlook is cautious due to persistent revenue declines and negative margins. While analyst consensus leans slightly bullish with 40.3% buy ratings, significant risks include execution challenges and competitive pressures. Investors should weigh the potential for a turnaround against ongoing operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
